Notable Reporting: Pain Therapeutics Inc (NASDAQ
TIE) Institutional Investor Sentiment Is 0.82
Shares Outstanding 46.14M
Float 38.4M
December 15, 2016 - By Richard Conner · 0 Comments
Notable Reporting: Pain Therapeutics Inc (NASDAQ TIE) Institutional Investor Sentiment Is 0.82
Sentiment for Pain Therapeutics Inc (NASDAQ TIE)
Pain Therapeutics Inc (NASDAQ TIE) institutional sentiment decreased to 0.82 in Q3 2016. Its down -0.49, from 1.31 in 2016Q2. The ratio worsened, as 14 investment managers increased or opened new equity positions, while 17 sold and decreased their holdings in Pain Therapeutics Inc. The investment managers in our partner’s database now have: 20.80 million shares , down from 22.53 million shares in 2016Q2 . Also, the number of investment managers holding Pain Therapeutics Inc in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 6 Reduced: 11 Increased: 8 New Position: 6.
Pain Therapeutics, Inc. is a biopharmaceutical company. The company has a market cap of $27.23 million. The Firm is focused on drug development efforts on disorders of the nervous system, such as chronic pain. It currently has negative earnings. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone .
About 129,006 shares traded hands. Pain Therapeutics, Inc. (NASDAQ TIE) has declined 75.21% since May 12, 2016 and is downtrending. It has underperformed by 84.37% the S&P500.
Analysts await Pain Therapeutics, Inc. (NASDAQ TIE) to report earnings on March, 7.
According to Zacks Investment Research, “Pain Therapeutics is developing a new generation of opioid painkillers. Opioids are drugs derived from the poppy plant. The company uses technology to reformulate opioid drugs, such as morphine, into new painkillers with improved clinical benefits. The company has four opioid painkillers in Phase II clinical trials. The company believes its drugs offer enhanced pain relief, fewer adverse side effects and reduced tolerance and addiction compared to existing opioid painkillers.”
Nantahala Capital Management Llc holds 0.47% of its portfolio in Pain Therapeutics, Inc. for 3.87 million shares. Bvf Inc Il owns 2.28 million shares or 0.43% of their US portfolio. Moreover, 683 Capital Management Llc has 0.05% invested in the company for 457,969 shares. The California-based David R. Rahn & Associates Inc. has invested 0.03% in the stock. Gagnon Securities Llc, a New York-based fund reported 69,466 shares.#img1#
PTIE Company Profile
Pain Therapeutics, Inc., incorporated on May 4, 1998, is a biopharmaceutical firm that develops drugs. The Firm is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.
More recent Pain Therapeutics, Inc. (NASDAQ TIE) news were published by: Thestreet.com which released: “For Pain Therapeutics CEO, 3 FDA Rejections Are Worth $23 Million” on September 26, 2016. Also Marketwatch.com published the news titled: “Pain Therapeutics receives FDA letter saying NDA for opioid analgesic can’t be …” on September 26, 2016. Zacks.com‘s news article titled: “Pain Therapeutics (PTIE) Down on CRL for Chronic Pain Drug” with publication date: September 28, 2016 was also an interesting one.
Pain Therapeutics Inc.-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
TIE) Institutional Investor Sentiment Is 0.82 Shares Outstanding 46.14M
Float 38.4M
December 15, 2016 - By Richard Conner · 0 Comments
Notable Reporting: Pain Therapeutics Inc (NASDAQ
TIE) Institutional Investor Sentiment Is 0.82 Sentiment for Pain Therapeutics Inc (NASDAQ
TIE) Pain Therapeutics Inc (NASDAQ
TIE) institutional sentiment decreased to 0.82 in Q3 2016. Its down -0.49, from 1.31 in 2016Q2. The ratio worsened, as 14 investment managers increased or opened new equity positions, while 17 sold and decreased their holdings in Pain Therapeutics Inc. The investment managers in our partner’s database now have: 20.80 million shares , down from 22.53 million shares in 2016Q2 . Also, the number of investment managers holding Pain Therapeutics Inc in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 6 Reduced: 11 Increased: 8 New Position: 6. Pain Therapeutics, Inc. is a biopharmaceutical company. The company has a market cap of $27.23 million. The Firm is focused on drug development efforts on disorders of the nervous system, such as chronic pain. It currently has negative earnings. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone .
About 129,006 shares traded hands. Pain Therapeutics, Inc. (NASDAQ
TIE) has declined 75.21% since May 12, 2016 and is downtrending. It has underperformed by 84.37% the S&P500. Analysts await Pain Therapeutics, Inc. (NASDAQ
TIE) to report earnings on March, 7. According to Zacks Investment Research, “Pain Therapeutics is developing a new generation of opioid painkillers. Opioids are drugs derived from the poppy plant. The company uses technology to reformulate opioid drugs, such as morphine, into new painkillers with improved clinical benefits. The company has four opioid painkillers in Phase II clinical trials. The company believes its drugs offer enhanced pain relief, fewer adverse side effects and reduced tolerance and addiction compared to existing opioid painkillers.”
Nantahala Capital Management Llc holds 0.47% of its portfolio in Pain Therapeutics, Inc. for 3.87 million shares. Bvf Inc Il owns 2.28 million shares or 0.43% of their US portfolio. Moreover, 683 Capital Management Llc has 0.05% invested in the company for 457,969 shares. The California-based David R. Rahn & Associates Inc. has invested 0.03% in the stock. Gagnon Securities Llc, a New York-based fund reported 69,466 shares.#img1#
PTIE Company Profile
Pain Therapeutics, Inc., incorporated on May 4, 1998, is a biopharmaceutical firm that develops drugs. The Firm is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.
More recent Pain Therapeutics, Inc. (NASDAQ
TIE) news were published by: Thestreet.com which released: “For Pain Therapeutics CEO, 3 FDA Rejections Are Worth $23 Million” on September 26, 2016. Also Marketwatch.com published the news titled: “Pain Therapeutics receives FDA letter saying NDA for opioid analgesic can’t be …” on September 26, 2016. Zacks.com‘s news article titled: “Pain Therapeutics (PTIE) Down on CRL for Chronic Pain Drug” with publication date: September 28, 2016 was also an interesting one. Pain Therapeutics Inc.-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
